Dennis Lanfear is a biotechnology pioneer and leader with a track record for entrepreneurial vision and achievement. He founded Coherus Biosciences in 2010, assuming the roles of President, CEO and Chairman, and quickly turned the company from a startup into the industry’s leading “pure play” in biosimilar drugs. Having recruited some of biotech’s most accomplished drug developers, Coherus has built a late stage pipeline of biosimilar treatments for inflammatory diseases and cancer. The team Mr. Lanfear put together is now delivering on its vision of improved access to high quality, life-changing medicines. Coherus is backed by more than $400M in capital raised from the public and private markets. This includes over $110M in net proceeds from an April 2015 follow-on public offering, over $80M in net proceeds from a November 2014 IPO, and over $220M in private financing. Collaborations with Daiichi Sankyo and Baxter International further strengthen the company’s global drug development agenda.

Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen, where he served as a Vice President with broad operational, product development and marketing responsibility. He spend 10 of those years running Amgen’s renowned Process Development Department, where he was tasked with integrating more than 2,500 operations and staff worldwide. Mr. Lanfear spearheaded multiple development programs for growth factors, somatotropins and neurotrophins, taking these products from preclinical to Phase 3. He reviewed and wrote sections of more than 20 INDs and several BLAs, and he had direct budgetary responsibility for the $135 million development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 Mr. Lanfear was named Amgen’s Vice President, Market Development. In this role, he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.

Prior to joining Amgen, Mr. Lanfear held positions at Baxter International and was also the founder and CEO of Saronyx, Inc., a drug development software services company. In 2005, he founded InteKrin Therapeutics, serving as President, CEO, and Chairman in 2010. He is an investor in and former director of Anthera Pharmaceuticals, and a former director of Insmed Therapeutics.

Mr. Lanfear currently serves on the board of directors of NEUVOGEN, Inc.

Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

Mats Wahlström, Lead Director, has served as a member of our Board of Directors since January 2012.

Mr. Wahlström serves as the Chief Executive Officer and Chairman of KMG Capital Partners, LLC since April 2012, Chairman of PCI | HealthDev since August 2010, and Chairman of Caduceus Medical Holdings, LLC since August 2010. He has served on the boards of directors of Getinge AB since March 2012 and Alteco Medical AB since October 2012. He served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, and as a director of Zynex Inc., an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGAA. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, Mr. Wahlström held various positions at Gambro AB in Sweden, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.

Mr. Wahlström has a B.S. degree in Economics and Business Administration from University of Lund, Sweden.

Dr. Newcomer spent the majority of his career with UnitedHealthcare, where he most recently served as Senior Vice President, Oncology and Genetics, focusing on improving the affordability and quality of oncology care. He joined UnitedHealthcare in 1991 as Chief Medical Officer. Earlier, Dr. Newcomer served as Medical Director for CIGNA Health Care of Kansas City and was a practicing oncologist for nine years. Dr. Newcomer serves on the boards of directors of Cellworks Group and Myriad Genetics. He received a B.S. degree in Biology from Nebraska Wesleyan University and a M.D. from the University of Nebraska-Omaha. Dr. Newcomer earned a Master’s Degree in Health and Health Care Administration and Management from the University of Wisconsin-Madison.

Charlie Newton is the Chief Financial Officer of Lyell Immunopharma, a NASDAQ-listed biotechnology company. Prior to joining Lyell, he served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at BofA Securities, Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, and Managing Director & Head of Western Region Healthcare Investment Banking at Morgan Stanley. Mr. Newton advised on approximately $200 billion in mergers and acquisitions and raised nearly $60 billion in capital during his investment banking career. Mr. Newton earned his MBA from the Tuck School at Dartmouth College as well as a B.S. in Finance from Miami University.

Jill O’Donnell-Tormey, PhD, is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute (“CRI”), a nonprofit organization dedicated exclusively to advancing immunotherapy to treat, control and cure all cancers. She joined the organization in 1987 and has been Chief Executive Officer since 1993. As a recognized leader and advocate for cancer immunotherapy, Dr. O’Donnell-Tormey has spearheaded programs at CRI designed to identify and advance promising combination immunotherapies as well as facilitate global coordination of clinical research initiatives across academia and industry. Dr. O’Donnell-Tormey serves on the boards of The City University of New York (“CUNY”), Richmond University Medical Center, and the Staten Island Foundation. Dr. O’Donnell-Tormey served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University. She holds a Doctor of Philosophy in cell biology from the SUNY Downstate Medical Center and earned a Bachelor of Science in chemistry from Fairleigh Dickinson University.

Ali J. Satvat has served as a member of our Board of Directors since May 2014.

Mr. Satvat is a Member of KKR and a senior leader of the Health Care industry team within KKR’s Americas Private Equity platform since January 2012. He has also served as a member of the board of directors of several organizations, including Cohera Medical, Inc. since October 2015, Arbor Pharmaceuticals, Inc. since January 2015 and PRA Health Sciences, Inc. since September 2013. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012, served as a director of Chiron Holdings (Kinetic Concepts, Inc. and LifeCell Corporation) and TZ Holdings (The TriZetto Group, Inc.) and was actively involved with many of the firm’s successful growth investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group, where he was involved in a broad range of transactions.

Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania.

Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association.

Mr. Stolper has served as Executive Vice President and Chief Financial Officer of RadNet, Inc., a publicly traded operator of medical diagnostic imaging centers, since July 2004. He has served on the board of directors of Surgalign Holdings, Inc., a publicly traded medical technology company, since March 2017, and Rotech Healthcare Inc., a privately held medical equipment company, since February 2016. Previously, Mr. Stolper served as a member of the board of directors of 21st Century Oncology Holdings, Inc., Surgical Solutions LLC, Physiotherapy Associates, Inc., Metropolitan Health Networks, Inc., and Compumed, Inc. Mr. Stolper graduated with a B.A. in Economics from the University of Pennsylvania and a B.S.E. in Finance from the Wharton School. Additionally, Mr. Stolper earned a postgraduate Award in Accounting from the University of California, Los Angeles.

Kim Tzoumakas joined the board as an independent director in August, 2020.

Ms. Tzoumakas has over 25 years of healthcare leadership experience, most recently as the former CEO and current Board Member of 21^st Century Oncology, one of the largest integrated cancer care networks in the world with revenue of $1 billion annually. She led the transformation of the company on behalf of the equity owners, including resolving significant financial and regulatory historical challenges, building a leadership team, rebranding and creating a culture, while developing a growth strategy which led to a successful sale to GenesisCare in May, 2020.  At the time of the sale, 21^st Century Oncology was a network of 3,000 team members, 900 physicians, 300+ locations in 15 states, and seven Latin American countries. The Latin America oncology care businesses was spun off and she continues to serve as President and Board Member of International Oncology Care, on behalf of its equity owners. She remains a board member of GenesisCare US and is the Chair of the Compliance Committee.

Previously, Ms. Tzoumakas served as a healthcare legal advisor to some of the  largest healthcare providers in the country for over 20 years. She managed the Michigan office of Hall Render, a national health care law firm, while serving on the firm’s board and working closely with health care boards around governance, strategy and mergers and acquisitions. As part of the firm’s growth committee, the firm expanded to 11 states during her tenure.  Throughout her career, she has maneuvered regulatory and strategic challenges for public and private companies and has served on the compensation committees, strategic growth committees and finance committees at various times.

Ms. Tzoumakas has a Bachelor’s in Business Administration from Northwood University and a Juris Doctorate from Thomas Cooley Law School where she graduated magna cum laude in 1996.